Cohance Lifesciences Ltd · NSE:COHANCE
Cohance Lifesciences — Suven Pharmaceuticals — Q3 FY22 Earnings Presentation
24 slides from Cohance Lifesciences's earnings presentation, February 2022
Slide 1: Suven Pharma Earnings Presentation Q3 & 9MFY22
SUVEN PHARMA Earnings Presentation Q3 & 9MFY22
Slide 2: Risk Statement
Risk Statement Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in
Slide 3: Table of Contents
4 14 Table of Operation & Financial Company Background Contents Performance Q3FY22 3
Slide 4: Operation & Financial Performance Q3FY22
Operation & Financial Performance Q3FY22 4
Slide 5: Businesswise data
Businesswise data CDMO Pharma CDMO Spec Chem Formulations & Other Ser vices 266.15 104.64 23.25 216.96 14.39 34.8 Q3FY21 Q3FY22 Q3FY21 Q3FY22 Q3FY21 Q3FY22 Note: Figures in Rs. Crore 5
Slide 6: Businesswise data
Businesswise data CDMO Pharma CDMO Spec Chem Formulations & Other 563.9 326.85 Ser vices 486.01 68.09 59.23 196.53 9MFY21 9MFY22 9MFY21 9MFY22 9MFY21 9MFY22 Note: Figures in Rs. Crore 6
Slide 7: Financial Snapshot
Financial Snapshot Q3FY22 9MFY22 Growth in Growth in Growth in Revenue EBITDA PAT 43.28% 37.37% 40.31% 32.60% 32.99% 36.63% 7
Slide 8: Key Ratios
Key Ratios Q3FY22 9MFY22 Growth in EBITDA to PAT to EBIT Income Income 38.51% 48.72% 34.18% 33.69% 50.82% 33.04% 8
Slide 9: Financials Q3FY22
Financials Q3FY22 Revenue EBIDTA PAT EPS 1,370 4,009 1,953 5.4 1,152 3,393 4.5 1,601 976 2,798 1,422 3.8 RUPEES MN RUPEES MN RUPEES MN RUPEES Q3FY21 Q2FY22 Q3FY22 Q3FY21 Q2FY22 Q3FY22 Q3FY21 Q2FY22 Q3FY22 Q3FY21 Q2FY22 Q3FY22 9
Slide 10: Financials 9MFY22
Financials 9MFY22 Revenue EBIDTA PAT EPS 10,098 4,758 13.1 3,336 7,615 3,578 2,442 9.6 RUPEES MN RUPEES MN RUPEES MN RUPEES 9MFY21 9MFY22 9MFY21 9MFY22 9MFY21 9MFY22 9MFY21 9MFY22 10
Slide 11: Financials Q3FY22
Financials Q3FY22 EBITDA Margin (%) PAT Margin (%) 51% 49% 47% 35% 34% 34% Q3FY21 Q2FY22 Q3FY22 Q3FY21 Q2FY22 Q3FY22 11
Slide 12: Financials 9MFY22
Financials 9MFY22 EBITDA Margin (%) PAT Margin (%) 47% 47% 32% 33% 9MFY21 9MFY22 9MFY21 9MFY22 12
Slide 13: Financial Table – Q3 FY22
Financial Table – Q3 FY22 Quarter ended Period ended 31-Dec-21 30-Sep-21 31-Dec-20 31-Dec-21 30-Dec-20 Revenue 4,008.60 3,393.23 2,797.76 10,097.67 7,614.93 EBITDA 1,953.02 1,601.10 1,421.77 4,758.12 3,577.68 EBITDA Margin 48.72% 47.19% 50.82% 47.12% 46.98% EBIT 1,847.96 1,509.33 1,334.20 4,471.36 3
Slide 14: Company Background
Company Background SUVEN 14 PHARMA
Slide 15: Business Model
Business Model Process Custom Research Synthesis Contract Development And Manufacturing Operations (CDMO) Formulation Clinical Development Supplies Mfg Analytical & & Packaging Services 15
Slide 16: Brief Profile
Brief Profile BUSINESS OVERVIEW o Integrated CDMO KEY STRENGTHS company with strong o Preferred global outsourcing FINANCIAL OVERVIEW capabilities right from partner with capabilities o Standalone Revenues, EBIT and PAT process research & across the entire CDMO of Rs 10,098 Mn, Rs 4,471 Mn and Rs de
Slide 17: Suven is an integrated Contract Development and Manufacturing Operations company
Suven is an integrated Contract Development and Manufacturing Operations company Suven provides services to leading Global Life Science and Fine Chemical majors including Custom Synthesis, Process R&D, Scale Up and Contract Manufacturing of intermediates, APIs and formulations. Since our founding in
Slide 18: Q3FY22 Business updates
Q3FY22 Business updates The Board has declared an interim Dividend of Rs.1.00 per equity share (100% of Face value of Rs.1.00 each) and one-time special dividend of Rs. 2.00 per equity share (200% of Face value of Rs.1.00), totaling to Rs. 3.00 per equity share (300% of Face value of Rs. 3.00 each)
Slide 19: NCE based CDMO
Our Focus NCE based A full-fledged bio- pharmaceutical solutions CDMO provider for global pharmaceutical companies 19 19
Slide 20: Financial Approach
Financial Approach Consistently Low dividend debt paying Shareholder Prudent value creation utilisation of focus cash flows 20
Slide 21: Business Drivers
Business Drivers Industry Relationship An integrated research service provider with Leveraging on unmatched capabilities research capabilities Present across the to delivering NCE entire CDMO value research chain – State of the art intermediates & facilities located APIs across India and US 21
Slide 22: Business Drivers
Business Drivers Execution Capabilities Over 90% of Working with revenues from innovator companies regulated in developed markets markets having stringent regulations – Long term reflection of our commercial supply research skills Repeat business with the launch of owing to long product by global st
Slide 23: Multi Location Facilities
Multi Location Facilities o o 300 CM reactors (93) 500L to 10 KL GL/SS o GMP Intermediates Vizag, Andhra Pashamylaram, Telangana, India Banjara Hills, Hyderabad, India Suryapet, Telangana, India Pradesh, India API & Formulation Facility Corporate Office Intermediate Mfg. Facility o 307 KL reactor vo
Slide 24: Contact
Contact For queries and requests, please contact: Suven Pharmaceuticals Ltd Suven Pharmaceuticals Ltd Email: info@suvenpharm.com For more info: www.suvenpharm.com # 8-2-334, SDE Serene Chambers, 3rd Floor, Road No. 5, Avenue - 7, Banjara Hills, Hyderabad-500 034, Telangana, INDIA. Gavin Desa / Risha
Suven Pharmaceuticals — Q3 FY22 Earnings Presentation on 6ix